Komori
Pharma Foods International (2929) · InitiativeAdvanced

Expanding sales of WMOA eyelash serum

First written in FY2022-Q2. 7 of 8 entries say "Advanced", first in FY2022-Q3. Latest entry: FY2026.

8entries
5years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2022-Q3 – FY20262022: 420222023: 220232024: 020242025: 020252026: 22026
Same theme, other companies
Expanding New Categories Including Hair Care and ShaversA theme 4 companies write about · 0 as a headwind · 4 as a tailwind

3 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Matsuge Deluxe WMOA, which became the category leader in eyelash serums following the Nyu-mo series, continued to recover its investment and was distributed to Loft stores, which attract consumers sensitive to beauty trends, creating new customer touchpoints.」

    WMOA became the category leader, and as investment recovery progressed, distribution through Loft stores created customer touchpoints outside direct-to-consumer sales.
  2. 2026-06-10AdvancedFinancial results briefing materials

    「The company's direct-to-consumer products, including the eyelash serum WMOA and the new cream shampoo KURUB, were stocked by retailers such as LOFT, attracting attention.」

    Expansion of sales channels for direct-to-consumer products, including WMOA, through distribution to retail stores became more concrete.
  3. FY2023AdvancedAnnual report

    「As a result, cumulative shipments exceeded 2.2 million units as of 31 July 2023.」

    Cumulative WMOA shipments increased from more than 700,000 units in the previous fiscal year to 2.2 million units, advancing the horizontal expansion of the ニューモ brand.
  4. FY2023-Q2AdvancedAnnual report

    「As a result of continuing advertising and promotion of the eyelash serum “まつ毛デラックスWMOA” as part of the horizontal expansion of the “ニューモ” brand, revenue was ¥2,930 million, up 195.3% year on year.」

    WMOA advertising and promotion continued, with revenue reaching ¥2,930 million, up 195.3% year on year.
  5. FY2023-Q1AdvancedAnnual report

    「As a result of continuing advertising and promotion of the eyelash serum “まつ毛デラックス WMOA” as part of the horizontal expansion of the “ニューモ®” brand, revenue was ¥1,488 million, compared with ¥74 million in the same period of the previous year.」

    WMOA revenue increased from ¥74 million in the same period of the previous year to ¥1,488 million, advancing the horizontal expansion of the ニューモ brand.
  6. FY2022AdvancedAnnual report

    「As part of the horizontal expansion of the “ニューモ®” brand, we worked on advertising and promoting the new eyelash serum “まつ毛デラックス WMOA.” Strong initial orders led to the initial production run selling out and inventory shortages, but shipments resumed in December 2021, and revenue was ¥2,794 million.」

    Following the sellout of the initial production run and inventory shortages, WMOA shipments resumed, and the product grew to full-year revenue of ¥2,794 million and cumulative shipments exceeding 700,000 units.
  7. FY2022-Q3AdvancedAnnual report

    「As part of the horizontal expansion of the “ニューモ®” brand, we worked on advertising and promoting the new eyelash serum “まつ毛デラックス WMOA.” Strong orders initially resulted in the initial production run selling out, but shipments resumed in December 2021, and revenue for the cumulative third quarter was ¥1,871 million.」

    WMOA generated revenue of ¥1,871 million after shipments resumed, marking progress in the horizontal expansion of the ニューモ brand.
  8. FY2022-Q2First statedAnnual report

    「As part of the horizontal expansion of the “ニューモ®” brand, we focused on advertising and promoting the eyelash serum “まつ毛デラックス WMOA.” Strong orders resulted in the initial production run selling out, but shipments resumed in December 2021, and revenue for the cumulative second quarter was ¥992 million.」

    As part of the horizontal expansion of the ニューモ brand, we invested in advertising for WMOA. Following the sellout of the initial production run and the resumption of shipments, cumulative second-quarter revenue reached ¥992 million.
Moved together

"Development of antibody therapeutics using proprietary chicken antibody technology" moved the same way as this thread, in the same document, in 7 of its 8 moves.

776555★123456
  1. ★This thread
  2. 1Development of antibody therapeutics using proprietary chicken antibody technology7×
  3. 2Raising Working Capital through Borrowings7×
  4. 3Advertising Investment and Product Brand Expansion in Mail-Order Sales6×
  5. 4GABA Expansion in Japan and Overseas5×
  6. 5Research and Development Expenditure5×
  7. 6Aggressive Business Investment to Achieve High Medium- to Long-Term Growth and Enhance Corporate Value5×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Pharma Foods International yet. It last moved in the Financial results briefing materials of 2026-06-10: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Expanding sales of WMOA eyelash serum | Pharma Foods International Co.,Ltd. (2929) | Komori